The involvement of pharmacy benefit managers (PBMs) in 340B is the “colliding of 2 worlds,” said Ted Okon, MBA, executive director, Community Oncology Alliance.
The involvement of pharmacy benefit managers (PBMs) in 340B is the “colliding of 2 worlds,” said Ted Okon, MBA, executive director, Community Oncology Alliance (COA).
Transcript
The COA has raised concerns about pharmacy benefit manager contracting in the 340B program. Do you think the FTC probe will impact this for the benefit of patients?
You know, we've really seen the colliding of 2 worlds, and that is 340B program, which is out of control, and the PBMs literally taking over the contract pharmacy world of 340B. That's why you have over 16 manufacturers that are now in litigation, because they have stopped selling to multiple contract pharmacies.
How this plays out is that the PBMs want drugs to come through their mail order and specialty pharmacy. In the world of oncology, it's why we see PBMs literally mandating more that they dispense the drugs through the mail, as opposed to the patient getting it right there at the practice. That causes delays. It causes denials. It causes waste when there are wrong dosages, and this happens a lot of the time. I think we're going to see more white bagging as well too of injectable drugs, because I think that the PBMs, again, through their specialty pharmacies, which are 340B contract pharmacies, want to see more drug come through them.
So, this is going to be a real problem. I'm not so sure that the FTC is really aware of this problem. We are going to make them aware of it. It's one of the reasons why COA recently filed an amicus brief for the [Eli] Lilly lawsuit with HHS of not selling to multiple contract pharmacies. And we are working on an amicus brief for the AstraZeneca lawsuit as well, too.
Not that we wanted to do Lilly or AstraZeneca a favor, but we wanted to basically inform the courts that this program, which was intended to help patients in need, is now going to the coffers of some of the largest corporations in this country.
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
FDA Grants Accelerated Approval to Ponatinib Plus Chemotherapy in First-Line Ph+ ALL
March 19th 2024The FDA has granted accelerated approval to ponatinib (Iclusig) plus chemotherapy for the first-line treatment pf Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
Read More